SAN DIEGO, November 18, 2014 – Profil Institute for Clinical Research, Inc., a clinical research organization (CRO) focused on diabetes and obesity, will present at the Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, taking place November 20-22 in Los Angeles. The presentation will take place on November 20 and is a ‘Meet the Expert’ session focused on the role of insulin resistance in the pathogenesis of type 2 diabetes and associated cardiometabolic disorders. The speaker, Prof. Andrew Krentz, is a key scientist at Profil Institute, as well as a co-author and editor of the forthcoming textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.
Topics discussed during the session will include:
- The role of insulin resistance in the pathogenesis of type 2 diabetes and associated cardiometabolic disorders and its importance as a therapeutic target
- Available insulin-sensitizing drugs and the prospects for novel agents currently in development
- Strengths and limitations of established methods together with some recent advances in the assessment of insulin action
More information about the Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease can be found at http://www.wcir.org.
For more information about Profil Institute, please visit www.profilinstitute.com.
About Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity. It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.
Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.
Profil Institute is also recognized internationally as an innovator of methodologies to improve the quality of metabolic research, including its Automated Glucose Clamp technology. As the leading early phase CRO focused on diabetes and obesity, Profil Institute is driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners and its Metabolic Research Partners™ program.
For further information, please contact: